ASCO 2026 Trends to Watch: Precision Oncology, AI and Real-World Impact
As the oncology community prepares for ASCO Annual Meeting 2026, attention is turning toward the technologies, data strategies, and scientific advances shaping the next phase of precision medicine.
The theme at ASCO 2026 is “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide,” which reflects the industry’s growing focus on translating innovation into real-world clinical impact.
Aligned with this year’s focus on translating innovation into real-world impact, several key trends are set to drive conversation across ASCO 2026, particularly the continued expansion of biomarker-driven precision medicine and the evolution of treatment strategies across the patient journey. Alongside these shifts, there is growing emphasis on translating complex data into clinical action, with AI playing an increasingly important enabling role.
Biomarker-Driven Precision Oncology Continues to Expand
Across tumor types, there is increasing emphasis on the role of molecular profiling, genomic testing and emerging biomarkers in guiding treatment decisions. As the number of targeted therapies continues to grow, so too does the complexity of ensuring patients are accurately identified and matched to appropriate treatment pathways.
Looking ahead to ASCO 2026, we expect continued focus on how biomarkers are being used across the full patient journey - from initial diagnosis and treatment selection through to response monitoring and disease progression. This includes increasing interest in circulating biomarkers such as ctDNA, supporting more adaptive and personalized approaches to care.
Alongside this, the expansion of targeted therapies including modalities such as antibody-drug conjugates (ADCs), bispecific antibodies and other next-generation treatments is increasing the importance of precise patient stratification and timely access to diagnostic testing.
However, despite advances in biomarker science, real-world implementation remains a significant challenge. Variability in testing rates, delays in diagnosis and fragmented data across laboratory and clinical systems continue to limit the ability to consistently identify eligible patients and access to biomarker-driven care
For pharmaceutical and biotech companies, this significantly raises the stakes. As biomarker-driven therapies expand, ensuring patients are accurately identified and tested at the right time becomes a critical determinant of clinical and commercial success.
As ASCO 2026 emphasizes translating scientific innovation into real-world impact, a key theme will be how to ensure biomarker insights are effectively integrated into routine clinical workflows and decision-making.
Precision Oncology Requires More Connected Commercial Strategies
As more biomarker-driven therapies enter increasingly competitive markets, pharmaceutical and biotech companies are facing growing pressure to improve testing adoption, accelerate physician readiness, and identify eligible patients earlier in the treatment pathway.
Success in precision oncology now depends not only on scientific innovation, but also on the ability to connect insights across diagnostics, laboratory testing, physician behavior, and real-world patient pathways.
There is growing demand for data-driven precision medicine strategies that help organizations:
- Identify missed testing opportunities
- Improve test-to-treatment conversion
- Support physician engagement
- Optimize launch readiness
- Strengthen precision oncology commercialization
AI in Oncology Is Moving From Exploration to Real-World impact
Artificial intelligence continues to reshape how healthcare organizations approach cancer diagnostics, clinical decision-making, and precision medicine strategy. Looking ahead, we expect the conversation to move beyond isolated AI use cases toward multimodal applications that integrate genomic, pathology, and real-world clinical data to support more precise patient identification and treatment decisions.
Across the oncology ecosystem, AI-enabled technologies are increasingly being used to support:
- Biomarker identification and testing optimization
- Patient stratification and treatment matching
- Real-world evidence generation
- Clinical workflow efficiency
- Data-driven physician engagement and commercialization strategies
Recent oncology conference programming and industry activity continue to highlight growing momentum around multimodal AI, computational oncology, and AI-supported clinical insights.
As precision oncology becomes more data-intensive, pharmaceutical and biotech companies are increasingly looking for ways to transform fragmented diagnostic, genomic, and clinical datasets into actionable intelligence that can improve patient identification, therapy adoption, and access to targeted treatments. However, many organizations still face challenges in integrating fragmented datasets and translating AI-driven insights into actionable driven insights within real-world clinical workflows.
As ASCO 2026 focuses on translating scientific advances into real-world impact, we expect increasing discussion around how AI can be used to improve diagnostic adoption, identify missed patients, and accelerate therapy uptake in real-world settings. For pharmaceutical and biotech companies, the opportunity lies not just in deploying AI, but in operationalizing insights across the full patient journey, from testing through to treatment, where the greatest gaps in precision oncology delivery still exist.
Meet Diaceutics at ASCO 2026
Schedule some time with our team at ASCO to discuss how we help you unlock the full potential of your diagnostic-driven therapies. Through working at the intersection of data, science, and commercial strategy, we focus on solving the real-world challenges that limit therapy uptake, helping you find missed patients, improve diagnostic pathways, and act at the moments that matter most.
Book a meeting with the Diaceutics team at ASCO 2026 or Contact Us to find out more about how our solutions can support your diagnostic‑driven therapy.
